Achmea Investment Management B.V. Acquires 67,362 Shares of Boston Scientific Co. (NYSE:BSX)

Achmea Investment Management B.V. grew its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 92.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 140,373 shares of the medical equipment provider's stock after purchasing an additional 67,362 shares during the quarter. Achmea Investment Management B.V.'s holdings in Boston Scientific were worth $12,538,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Boston Scientific by 4.4% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider's stock valued at $345,205,000 after purchasing an additional 173,034 shares during the period. Mechanics Bank Trust Department acquired a new position in shares of Boston Scientific in the 4th quarter valued at about $415,000. Highland Capital Management LLC acquired a new position in Boston Scientific during the 4th quarter worth approximately $4,887,000. Covenant Asset Management LLC acquired a new position in Boston Scientific during the 4th quarter worth approximately $3,405,000. Finally, Brookstone Capital Management raised its stake in Boston Scientific by 23.7% during the 4th quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider's stock worth $9,455,000 after buying an additional 20,307 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Jeffrey B. Mirviss sold 4,675 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the transaction, the executive vice president now directly owns 28,454 shares of the company's stock, valued at $2,966,329.50. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Daniel J. Brennan sold 67,333 shares of the firm's stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total value of $7,086,124.92. Following the completion of the transaction, the chief financial officer now directly owns 225,808 shares of the company's stock, valued at $23,764,033.92. The trade was a 22.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 137,302 shares of company stock valued at $14,319,269 over the last ninety days. 0.50% of the stock is currently owned by insiders.

Remove Ads

Boston Scientific Stock Performance

Shares of BSX traded up $0.27 on Tuesday, reaching $99.17. 5,369,981 shares of the company's stock traded hands, compared to its average volume of 5,742,343. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The stock has a market cap of $146.36 billion, a PE ratio of 79.34, a PEG ratio of 2.79 and a beta of 0.77. The stock's 50 day simple moving average is $101.21 and its two-hundred day simple moving average is $91.97. Boston Scientific Co. has a 52-week low of $66.16 and a 52-week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on BSX. Stifel Nicolaus upped their price target on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. Morgan Stanley upped their price target on Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a research note on Friday, January 10th. Piper Sandler upped their price target on Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Boston Scientific in a research note on Monday, March 3rd. Two analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $108.91.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.